Skip to main content
Premium Trial:

Request an Annual Quote

Genoox Integrated Platform

Bionano Genomics and Genoox have launched the Genoox Integrated Platform for identification of structural variants. The companies said in April that they had partnered to develop a genome informatics workflow, which would integrate and annotate Bionano's structural variant calls with sequencing data within the Genoox platform.

Bionano said that the Saphyr system, combined with the firm's new DLS labeling chemistry and analysis tools, calls structural variants better than sequencing-based methods. By applying Genoox's variant classification technology to align short read sequence data to its structural variant calls, the high sensitivity of Bionano calls would be combined with the base-pair precision of NGS. The Genoox Integrated Platform further automatically validates and confirms structural variant calls, in addition to integrating and annotating structural variants with smaller sequence variants in the same genome, the firms said. The tool provides sensitive, accurate detection of structural variation and genetic mutations, helping to speed genetic diagnosis.

The new platform combines raw NGS read data with Bionano-based structural variant calls from a single patient. Researchers then use Bionano's structural variant data to guide the alignment of NGS reads. Detected structural variants, copy number variants, indels, and single nucleotide variants are then annotated by aggregating data from multiple clinical and population frequency databases, and automated AI-based classification according to ACMG guidelines, the companies said. The platform then generates a customized clinical report on all variants, including Bionano-only and NGS-only calls. Genoox and Bionano will co-sell and co-market the integrated platform.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.